Dec 12, 2019 7:00am EST Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform
Nov 18, 2019 7:30am EST Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference
Nov 13, 2019 6:30am EST Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Nov 06, 2019 7:30am EST Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019
Oct 14, 2019 7:00am EDT Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis
Oct 07, 2019 7:00am EDT Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis
Sep 25, 2019 7:00am EDT Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®
